

REMARKS

Status of Claims

Claims 76-86 are currently pending in the application.

Supplemental Information Disclosure Statement

Pursuant to 37 CFR §1.97 and §1.98, Applicants submit herewith a Supplemental Information Disclosure Statement and request that the Examiner consider and make of record the references cited therein.

Rejection under 35 U.S.C. §101

Claims 76-84 are rejected under 35 U.S.C. §101 as the claims are allegedly directed to non-statutory subject matter. The Examiner argues that the claimed antibodies encompass naturally occurring antibodies which read on products of nature.

Without acquiescing to the rejection and solely to advance prosecution, Claim 76 has been amended to recite an "isolated" antibody.


Objection to the Claims

Claims 79-86 are objected to for having the word "thereof" omitted. It is argued that the claims should read "the antibody or fragment thereof of claim ...". The claims have been amended to make this correction.

CONCLUSION

It is believed that Claims 76-86 are in condition for allowance and a notice thereof is solicited.

Respectfully submitted,


Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date: May 6, 2009

Please send all future correspondence to:

21069

US Patent Operations/RBW
Dept. 4300, M/S 28-2-C
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799